The drug Alostra, based on human cells donated by healthy people, was developed at Hadassah in collaboration with the biotechnology company Analybax Therapeutics. • Its use is the world's first clinical trial in Corona patients.
Hadassah Ein Kerem Hospital
Photography:
Moshe Shai
Positive news in the fight against Corona
: Hadassah Hospital announced that today (Wednesday) the fifth patient among the most difficult and critical patients was released to his home, who received innovative treatment as part of the world's first clinical trial, treating human cells taken from a healthy donor.
The five corona patients;
3 of them in critical condition and 2 in critical condition, were treated at Hadassah Ein Kerem Hospital under a clinical trial with an innovative drug - Alostra, developed at Hadassah in collaboration with the biotechnology company Analybex Therapeutics. The drug, and all were negative for the corona virus on the day of release.
Alostra was developed on the basis of research by Prof. Dror Mevorach, director of the internal medicine and corona wards at Hadassah, and has already been successfully tested in the past in ten patients with sepsis (sepsis), which is considered a serious disease that currently has no cure.
"Alostra is intended for the treatment of a wide range of cases in which there is an overactivity of the immune system, which leads to an increase in the secretion of proteins by cells of the immune system. The cells are called cytokines and cause a cytokine storm," explains Prof. Mevorach.
"Its activity is carried out by treating cells taken from a healthy donor and induced in the laboratory in such a way that they, when injected into the patient's body, curb the inflammation or cytokine storm that is very harmful to patients."
The trial in Corona patients was conducted under the approval of the Helsinki Committee of the Ministry of Health, and the lead researcher in the trial was Prof. Van Hayarden, director of the Intensive Care Unit at Hadassah Ein Kerem Hospital.
"We are pleased that the patients in a difficult and critical condition have recovered from the treatment with Allstra," the company said.
Hadassah CEO Prof. Zeev Rothstein said: "Despite the war around and alongside intensive preparations to absorb the growing numbers of critically ill patients, Hadassah continues to innovate and lead the breakthroughs in treating these corona patients and are pleased that a drug developed in research within our hospital walls shows therapeutic potential. In these patients. "